Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares IssuedShares Repurchased
Daily Values
Growth Metrics
Income Statement
Others
Ratios

C4 Therapeutics (CCCC) Free Cash Flow: 2019-2025

Historic Free Cash Flow for C4 Therapeutics (CCCC) over the last 6 years, with Sep 2025 value amounting to -$31.5 million.

  • C4 Therapeutics' Free Cash Flow fell 30.63% to -$31.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$94.8 million, marking a year-over-year decrease of 32.42%. This contributed to the annual value of -$65.3 million for FY2024, which is 39.81% up from last year.
  • Latest data reveals that C4 Therapeutics reported Free Cash Flow of -$31.5 million as of Q3 2025, which was down 161.33% from -$12.1 million recorded in Q2 2025.
  • C4 Therapeutics' 5-year Free Cash Flow high stood at -$5.2 million for Q2 2024, and its period low was -$33.7 million during Q1 2023.
  • Its 3-year average for Free Cash Flow is -$22.8 million, with a median of -$24.1 million in 2024.
  • In the last 5 years, C4 Therapeutics' Free Cash Flow soared by 73.29% in 2024 and then plummeted by 133.17% in 2025.
  • Over the past 5 years, C4 Therapeutics' Free Cash Flow (Quarterly) stood at -$25.8 million in 2021, then decreased by 18.77% to -$30.6 million in 2022, then increased by 21.07% to -$24.2 million in 2023, then grew by 25.81% to -$17.9 million in 2024, then tumbled by 30.63% to -$31.5 million in 2025.
  • Its last three reported values are -$31.5 million in Q3 2025, -$12.1 million for Q2 2025, and -$33.3 million during Q1 2025.